Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Pediatric Rheumatology
What additional immunomodulation would you consider in a patient with severe NXP-2+ JDM who has already received cyclophosphamide and rituximab but has persistent gastrointestinal vasculopathy?
Answer from: at Academic Institution
I'd try a JAKi.
Sign In
or
Register
to read more
19547
Related Questions
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
What are your preferred alternative biologic agents for Blau Syndrome when anti-TNFα therapies are contraindicated?
Do you continue biologics in sJIA patients who develop lung disease on anti IL-1 or anti IL-6 therapies?
Do you recommend genetic screening for FMF in asymptomatic first-degree relatives with a strong family history (multiple family members, severe/refractory disease)?
In a patient with SJIA who has been stable on Anakinra however is now planning to conceive or becomes pregnant, would you consider switching to Cimzia?
How would you approach a patient with SLE and class II LN who has persistent lupus activity and incomplete B-cell depletion on rituximab therapy?
What is your approach to screening patients with sJIA for associated lung disease?
In a young patient who was vaccinated to chickenpox as a child (no previous varicella infection) should the patient receive a shingles vaccine prior to starting Rinvoq?
How do you treat MAS in patients with systemic JIA or AOSD with HLA-DRB1*15 alleles given risk for DRESS hypersensitivity to IL1 or IL6 inhibitor therapy?